- Home
- PTGX vs RCKT Comparison
PTGX vs RCKT Comparison
Compare PTGX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTGX
- RCKT
- Stock Information
- Founded
- PTGX 2006
- RCKT 1999
- Country
- PTGX United States
- RCKT United States
- Employees
- PTGX N/A
- RCKT N/A
- Industry
- PTGX Biotechnology: Pharmaceutical Preparations
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- PTGX Health Care
- RCKT Health Care
- Exchange
- PTGX Nasdaq
- RCKT Nasdaq
- Market Cap
- PTGX 2.8B
- RCKT 1.9B
- IPO Year
- PTGX 2016
- RCKT N/A
- Fundamental
- Price
- PTGX $47.91
- RCKT $17.13
- Analyst Decision
- PTGX Strong Buy
- RCKT Strong Buy
- Analyst Count
- PTGX 7
- RCKT 9
- Target Price
- PTGX $52.83
- RCKT $53.22
- AVG Volume (30 Days)
- PTGX 450.1K
- RCKT 731.3K
- Earning Date
- PTGX 11-08-2024
- RCKT 11-04-2024
- Dividend Yield
- PTGX N/A
- RCKT N/A
- EPS Growth
- PTGX N/A
- RCKT N/A
- EPS
- PTGX 2.75
- RCKT N/A
- Revenue
- PTGX $319,120,000.00
- RCKT N/A
- Revenue This Year
- PTGX $400.33
- RCKT N/A
- Revenue Next Year
- PTGX N/A
- RCKT $300.20
- P/E Ratio
- PTGX $17.54
- RCKT N/A
- Revenue Growth
- PTGX 125.73
- RCKT N/A
- 52 Week Low
- PTGX $13.76
- RCKT $15.98
- 52 Week High
- PTGX $48.89
- RCKT $32.53
- Technical
- Relative Strength Index (RSI)
- PTGX 60.40
- RCKT 46.41
- Support Level
- PTGX $45.33
- RCKT $17.05
- Resistance Level
- PTGX $48.89
- RCKT $17.75
- Average True Range (ATR)
- PTGX 1.28
- RCKT 0.72
- MACD
- PTGX 0.11
- RCKT 0.06
- Stochastic Oscillator
- PTGX 77.11
- RCKT 40.23
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.